Literature DB >> 31386727

Nanopatterning protein antigens to refocus the immune response.

Ammar Arsiwala1, Chad Varner, Jessica N McCaffery, Andrew Kell, Geetanjali Pendyala, Ana Castro, Vivek Hariharan, Alberto Moreno, Ravi S Kane.   

Abstract

Vaccines for many important diseases remain elusive, and those for others need to be updated frequently. Vaccine efficacy has been hindered by existing sequence diversity in proteins and by newly-acquired mutations that enable escape from vaccine-induced immune responses. To address these limitations, we developed an approach for nanopatterning protein antigens that combines the site-specific incorporation of non-canonical amino acids with chemical modification to focus the immune response on conserved protein regions. We demonstrated the approach using green fluorescent protein (GFP) as a model antigen and with a promising malaria vaccine candidate, Merozoite surface protein 119 (MSP119). Immunization of mice with nanopatterned MSP119 elicited antibodies that recognized MSP119 from heterologous strains, differing in sequence at as many as 21 of 96 residues. Nanopatterning should enable the elicitation of broadly protective antibodies against a wide range of pathogens and toxins.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31386727      PMCID: PMC6705394          DOI: 10.1039/c9nr05145g

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  2 in total

1.  Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization.

Authors:  Shiho Chiba; Steven J Frey; Peter J Halfmann; Makoto Kuroda; Tadashi Maemura; Jie E Yang; Elizabeth R Wright; Yoshihiro Kawaoka; Ravi S Kane
Journal:  Commun Biol       Date:  2021-05-19

2.  Refocusing the Immune Response to Selected Epitopes on a Zika Virus Protein Antigen by Nanopatterning.

Authors:  Ana Castro; Juan Manuel Carreño; James Duehr; Florian Krammer; Ravi S Kane
Journal:  Adv Healthc Mater       Date:  2021-04-30       Impact factor: 11.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.